Grant Number:	1U01CA127615-01A1 Interpret this number
Primary Investigator:	Wu, Xifeng
Organization:	University Of Tx Md Anderson Can Ctr
Project Title:	Genome-Wide Association Analysis of Bladder Cancer
Fiscal Year:	2008

DESCRIPTION (provided by applicant): This proposal builds on a rich resource of bladder cancer (BC) cases and controls derived from two ongoing BC studies at the University of Texas M.D. Anderson Cancer Center, and from two large independent U.S. BC studies - the New England BC Study and the New Hampshire BC Study. The goal is to identify genetic loci that predispose individuals to BC through a genome-wide scanning approach. There are five specific aims. Aim 1 is to first perform genome-wide, high-density SNP genotyping using the Illumina HumanHap550 SNP platform on 800 cases and 800 controls from M.D. Anderson, with a target of candidate SNPs of about 28,000; followed by an internal validation to narrow down candidate SNPs to about 1,536 using additional 800 pairs of cases and controls. Illumina's Custom Infinium array will be the genotyping format. In this aim, in addition to individual SNP analysis, we will also implement haplotype-based analyses and pathway aggregation analysis to identify additional genetic loci that might have been overlooked using individual SNP analysis. Aim 2 is the first external validation of the 1,536 SNPs from Aim 1 using 1,000 pairs of cases and controls from the New England BC Study. Illumina's GoldenGate assay will be the genotyping format. After this stage, the candidate SNPs will be narrowed down to about 100. Aim 3 is the second independent external validation using 750 pairs of cases and controls form the New Hampshire BC Study. In this aim, the 100 top candidate SNPs passed from Aims 1 and 2 plus additional functional SNPs in genes containing these SNPs will be genotyped. GoldenGate assay will be used for this aim. Aim 4 is to perform fine mapping studies in the flanking regions of each of the top 25 SNP loci confirmed in Aim 3 to identify causative loci. This will utilize all 6,700 cases and controls. An average of 15 additional SNPs (tagging SNPs and functional SNPs) per gene is expected. Aim 5 is to apply novel machine-learning tools to identify any gene-environment and gene-gene interactions greatly influencing risk for BC in all the 6700 subjects. These analyses will be utilized to examine SNP main effect and develop and validate algorithms that will identify individuals at highest risk for BC, given their personal exposure patterns and their genetic risk profiles. This proposal applies state of art technology to perform a multistage, genome-wide SNP analysis in three largest, well-characterized U.S. population of BC cases and controls, and incorporates complete epidemiologic data and rich and unique functional data. In addition, results from this study will be provided to the International Consortium of BC Case Control Studies for future validation. The ability to identify genetically susceptible, high-risk subgroups that would benefit from intensive screening and/or chemopreventive interventions is of immense clinical and public health benefit. PUBLIC HEALTH RELEVANCE Bladder cancer (BC) is a disease mainly caused by smoking and occupational exposure. However, only a small percentage of exposed individuals develop BC. Inherited host genetic factors may play an important role in determining an individual's susceptibility to BC. This proposal builds on three largest well-characterized U.S. populations of BC cases and controls - the M. D. Anderson BC study, the New England BC Study and the New Hampshire BC Study. A total of 6700 cases and controls will be used. The goal is to identify genetic loci that predispose individuals to BC through a non-biased, discovery- driven, genome-wide scanning approach and to incorporate complete epidemiologic data and rich and unique functional data. About 550,000 genetic variations of human genome will be initially screened in an M.D. Anderson population consisting of an equal number of BC cases and normal controls. About 28,000 top candidate variations that are potentially associated with increased BC risk will be first narrowed down and internally replicated in a second M.D. Anderson population, and then be validated in the other two independent U.S. BC populations. Finally, the causative genetic loci that predispose individuals to BC will be mapped. This study is significant because by identifying BC susceptibility loci, it will shed light into the biological mechanisms of BC etiology. Furthermore, it may facilitate identifying high-risk subgroups of individuals for BC, given their genetic makeup and environmental exposures. The ability to identify high-risk subgroups of individuals for BC will provide immense public health benefit for those high- risk people who may be subjected to close surveillance and chemoprevention.




Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer.
Authors: Lian J. , Lin S.H. , Ye Y. , Chang D.W. , Huang M. , Dinney C.P. , Wu X. .
Source: Oncotarget, 2018-03-13 00:00:00.0; 9(19), p. 14895-14908.
EPub date: 2018-02-12 00:00:00.0.
PMID: 29599914
Related Citations

Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin.
Authors: Williams S.B. , Kamat A.M. , Mmeje C. , Ye Y. , Huang M. , Chang D.W. , Dinney C.P. , Wu X. .
Source: Oncotarget, 2017-10-24 00:00:00.0; 8(51), p. 88782-88791.
EPub date: 2017-09-23 00:00:00.0.
PMID: 29179475
Related Citations

Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer.
Authors: Lin M. , Zhang L. , Hildebrandt M.A.T. , Huang M. , Wu X. , Ye Y. .
Source: Oncotarget, 2017-09-26 00:00:00.0; 8(43), p. 74936-74946.
EPub date: 2017-08-24 00:00:00.0.
PMID: 29088836
Related Citations

High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.
Authors: Qu K. , Gu J. , Ye Y. , Williams S.B. , Dinney C.P. , Wu X. , Kamat A. .
Source: Oncoimmunology, 2017; 6(2), p. e1265719.
EPub date: 2017-01-03 00:00:00.0.
PMID: 28344874
Related Citations

Pathway Analysis Of Bladder Cancer Genome-wide Association Study Identifies Novel Pathways Involved In Bladder Cancer Development
Authors: Chen M. , Rothman N. , Ye Y. , Gu J. , Scheet P.A. , Huang M. , Chang D.W. , Dinney C.P. , Silverman D.T. , Figueroa J.D. , et al. .
Source: Genes & Cancer, 2016 Jul; 7(7-8), p. 229-239.
PMID: 27738493
Related Citations

Mirna-related Genetic Variations Associated With Radiotherapy-induced Toxicities In Patients With Locally Advanced Non-small Cell Lung Cancer
Authors: Li R. , Pu X. , Chang J.Y. , Ye Y. , Komaki R. , Minna J.D. , Roth J.A. , Han B. , Wu X. .
Source: Plos One, 2016; 11(3), p. e0150467.
PMID: 26991123
Related Citations

Genetic Variants In The Wnt/ß-catenin Signaling Pathway As Indicators Of Bladder Cancer Risk
Authors: Pierzynski J.A. , Hildebrandt M.A. , Kamat A.M. , Lin J. , Ye Y. , Dinney C.P. , Wu X. .
Source: The Journal Of Urology, 2015 Dec; 194(6), p. 1771-6.
PMID: 26173102
Related Citations

Genetic Variations In Glutathione Pathway Genes Predict Cancer Recurrence In Patients Treated With Transurethral Resection And Bacillus Calmette-guerin Instillation For Non-muscle Invasive Bladder Cancer
Authors: Ke H.L. , Lin J. , Ye Y. , Wu W.J. , Lin H.H. , Wei H. , Huang M. , Chang D.W. , Dinney C.P. , Wu X. .
Source: Annals Of Surgical Oncology, 2015 Nov; 22(12), p. 4104-10.
PMID: 25851338
Related Citations

Mitochondrial Dna Content As Risk Factor For Bladder Cancer And Its Association With Mitochondrial Dna Polymorphisms
Authors: Williams S.B. , Ye Y. , Huang M. , Chang D.W. , Kamat A.M. , Pu X. , Dinney C.P. , Wu X. .
Source: Cancer Prevention Research (philadelphia, Pa.), 2015 Jul; 8(7), p. 607-13.
PMID: 25896234
Related Citations

Depressive Symptoms And Short Telomere Length Are Associated With Increased Mortality In Bladder Cancer Patients
Authors: Lin J. , Blalock J.A. , Chen M. , Ye Y. , Gu J. , Cohen L. , Cinciripini P.M. , Wu X. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2015 Feb; 24(2), p. 336-43.
PMID: 25416716
Related Citations

Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer.
Authors: Pu X. , Wang L. , Chang J.Y. , Hildebrandt M.A. , Ye Y. , Lu C. , Skinner H.D. , Niu N. , Jenkins G.D. , Komaki R. , et al. .
Source: Clinical Pharmacology And Therapeutics, 2014 Nov; 96(5), p. 609-15.
PMID: 25054431
Related Citations

Genome-wide Association Study Identifies Multiple Loci Associated With Bladder Cancer Risk
Authors: Figueroa J.D. , Ye Y. , Siddiq A. , Garcia-Closas M. , Chatterjee N. , Prokunina-Olsson L. , Cortessis V.K. , Kooperberg C. , Cussenot O. , Benhamou S. , et al. .
Source: Human Molecular Genetics, 2014-03-01 00:00:00.0; 23(5), p. 1387-98.
PMID: 24163127
Related Citations

¿-h2ax Level In Peripheral Blood Lymphocytes As A Risk Predictor For Bladder Cancer
Authors: Fernández M.I. , Gong Y. , Ye Y. , Lin J. , Chang D.W. , Kamat A.M. , Wu X. .
Source: Carcinogenesis, 2013 Nov; 34(11), p. 2543-7.
PMID: 23946494
Related Citations

Genome-wide Association Study Of Genetic Predictors Of Overall Survival For Non-small Cell Lung Cancer In Never Smokers
Authors: Wu X. , Wang L. , Ye Y. , Aakre J.A. , Pu X. , Chang G.C. , Yang P.C. , Roth J.A. , Marks R.S. , Lippman S.M. , et al. .
Source: Cancer Research, 2013-07-01 00:00:00.0; 73(13), p. 4028-38.
PMID: 23704207
Related Citations

Genetic Variations In Micro-rna Biogenesis Genes And Clinical Outcomes In Non-muscle-invasive Bladder Cancer
Authors: Ke H.L. , Chen M. , Ye Y. , Hildebrandt M.A. , Wu W.J. , Wei H. , Huang M. , Chang D.W. , Dinney C.P. , Wu X. .
Source: Carcinogenesis, 2013 May; 34(5), p. 1006-11.
PMID: 23322153
Related Citations

Genetic Variations In Regulator Of G-protein Signaling (rgs) Confer Risk Of Bladder Cancer
Authors: Lee E.K. , Ye Y. , Kamat A.M. , Wu X. .
Source: Cancer, 2013-05-01 00:00:00.0; 119(9), p. 1643-51.
PMID: 23529717
Related Citations

Application Of Multi-snp Approaches Bayesian Lasso And Auc-rf To Detect Main Effects Of Inflammatory-gene Variants Associated With Bladder Cancer Risk
Authors: de Maturana E.L. , Ye Y. , Calle M.L. , Rothman N. , Urrea V. , Kogevinas M. , Petrus S. , Chanock S.J. , Tardón A. , García-Closas M. , et al. .
Source: Plos One, 2013; 8(12), p. e83745.
PMID: 24391818
Related Citations

Systematic Evaluation Of Apoptotic Pathway Gene Polymorphisms And Lung Cancer Risk
Authors: Lin J. , Lu C. , Stewart D.J. , Gu J. , Huang M. , Chang D.W. , Lippman S.M. , Wu X. .
Source: Carcinogenesis, 2012 Sep; 33(9), p. 1699-706.
PMID: 22665367
Related Citations

Germline Prognostic Markers For Urinary Bladder Cancer: Obstacles And Opportunities
Authors: Chang D.W. , Gu J. , Wu X. .
Source: Urologic Oncology, 2012 Jul-Aug; 30(4), p. 524-32.
PMID: 22742565
Related Citations

Comprehensive Pathway-based Interrogation Of Genetic Variations In The Nucleotide Excision Dna Repair Pathway And Risk Of Bladder Cancer
Authors: Xing J. , Dinney C.P. , Shete S. , Huang M. , Hildebrandt M.A. , Chen Z. , Gu J. .
Source: Cancer, 2012-01-01 00:00:00.0; 118(1), p. 205-15.
PMID: 21692063
Related Citations

Genetic Variants In Telomere-maintenance Genes And Bladder Cancer Risk
Authors: Chang J. , Dinney C.P. , Huang M. , Wu X. , Gu J. .
Source: Plos One, 2012; 7(2), p. e30665.
PMID: 22363464
Related Citations

Association Of Polymorphisms In Oxidative Stress Genes With Clinical Outcomes For Bladder Cancer Treated With Bacillus Calmette-guérin
Authors: Wei H. , Kamat A. , Chen M. , Ke H.L. , Chang D.W. , Yin J. , Grossman H.B. , Dinney C.P. , Wu X. .
Source: Plos One, 2012; 7(6), p. e38533.
PMID: 22701660
Related Citations

Genetic Variations In The Transforming Growth Factor Beta Pathway As Predictors Of Bladder Cancer Risk
Authors: Wei H. , Kamat A.M. , Aldousari S. , Ye Y. , Huang M. , Dinney C.P. , Wu X. .
Source: Plos One, 2012; 7(12), p. e51758.
PMID: 23251617
Related Citations

HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer.
Authors: Andrew A.S. , Hu T. , Gu J. , Gui J. , Ye Y. , Marsit C.J. , Kelsey K.T. , Schned A.R. , Tanyos S.A. , Pendleton E.M. , et al. .
Source: Plos One, 2012; 7(12), p. e51301.
PMID: 23284679
Related Citations

A Genome-wide Association Study Of Bladder Cancer Identifies A New Susceptibility Locus Within Slc14a1, A Urea Transporter Gene On Chromosome 18q12.3
Authors: Garcia-Closas M. , Ye Y. , Rothman N. , Figueroa J.D. , Malats N. , Dinney C.P. , Chatterjee N. , Prokunina-Olsson L. , Wang Z. , Lin J. , et al. .
Source: Human Molecular Genetics, 2011-11-01 00:00:00.0; 20(21), p. 4282-9.
PMID: 21824976
Related Citations

Genetic Susceptibility To Bladder Cancer Risk And Outcome
Authors: Gu J. , Wu X. .
Source: Personalized Medicine, 2011 May; 8(3), p. 365-374.
PMID: 21927616
Related Citations

A Genome-wide Association Study Identifies A Locus On Chromosome 14q21 As A Predictor Of Leukocyte Telomere Length And As A Marker Of Susceptibility For Bladder Cancer
Authors: Gu J. , Chen M. , Shete S. , Amos C.I. , Kamat A. , Ye Y. , Lin J. , Dinney C.P. , Wu X. .
Source: Cancer Prevention Research (philadelphia, Pa.), 2011 Apr; 4(4), p. 514-21.
PMID: 21460395
Related Citations

A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity.
Authors: Gu J. , Ye Y. , Spitz M.R. , Lin J. , Kiemeney L.A. , Xing J. , Hildebrandt M.A. , Ki Hong W. , Amos C.I. , Wu X. .
Source: Human Molecular Genetics, 2011-02-15 00:00:00.0; 20(4), p. 820-6.
EPub date: 2011-02-15 00:00:00.0.
PMID: 21106707
Related Citations

Genetic Variations In The Sonic Hedgehog Pathway Affect Clinical Outcomes In Non-muscle-invasive Bladder Cancer
Authors: Chen M. , Hildebrandt M.A. , Clague J. , Kamat A.M. , Picornell A. , Chang J. , Zhang X. , Izzo J. , Yang H. , Lin J. , et al. .
Source: Cancer Prevention Research (philadelphia, Pa.), 2010 Oct; 3(10), p. 1235-45.
PMID: 20858759
Related Citations

Prostate Stem Cell Antigen: A Jekyll And Hyde Molecule?
Authors: Saeki N. , Gu J. , Yoshida T. , Wu X. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2010-07-15 00:00:00.0; 16(14), p. 3533-8.
PMID: 20501618
Related Citations

Genetic Variants And Risk Of Lung Cancer In Never Smokers: A Genome-wide Association Study
Authors: Li Y. , Sheu C.C. , Ye Y. , de Andrade M. , Wang L. , Chang S.C. , Aubry M.C. , Aakre J.A. , Allen M.S. , Chen F. , et al. .
Source: The Lancet. Oncology, 2010 Apr; 11(4), p. 321-30.
PMID: 20304703
Related Citations

Genome-wide Association Studies Of Bladder Cancer Risk: A Field Synopsis Of Progress And Potential Applications
Authors: Wu X. , Hildebrandt M.A. , Chang D.W. .
Source: Cancer Metastasis Reviews, 2009 Dec; 28(3-4), p. 269-80.
PMID: 20016998
Related Citations

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.
Authors: Wu X. , Ye Y. , Kiemeney L.A. , Sulem P. , Rafnar T. , Matullo G. , Seminara D. , Yoshida T. , Saeki N. , Andrew A.S. , et al. .
Source: Nature Genetics, 2009 Sep; 41(9), p. 991-5.
PMID: 19648920
Related Citations